Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence

弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型

基本信息

项目摘要

Project Summary/Abstract Francisella tularensis is a bacterium that causes tularemia, a disease which, when in its pneumonic form, can be fatal even with appropriate treatment. Due to its low infectious dose, ease of spread by aerosol, and high virulence, F. tularensis is classified as a Tier 1 Select Agent by the U.S. federal government. This R01 project builds on our earlier identification (by contact PI Horwitz's group) of the Francisella Type VI Secretion System (T6SS) and our subsequent determination (by Horwitz's and MPI Zhou's group) of the first atomic models of its sheath and its uniquely endowed central spike complex through cryo electron microscopy (cryoEM). T6SSs are large, complex, multi-protein nanomachines that Gram-negative bacteria use to sense environmental cues and deliver toxins into other bacteria or into eukaryotic hosts; in Francisella, they mediate phagosome escape and intracytoplasmic replication. They are important virulence determinants, present in 25% of Gram-negative bacteria and in an even higher percentage of those that are human pathogens. However, without knowing T6SS composition and structure, we cannot fully understand its mechanisms of pathogenesis nor effectively design countermeasures against a myriad of bacterial diseases. The T6SS of Francisella is both significant and attractive to study because of the high infectivity and lethality of Francisella species and its relative simplicity compared with other T6SSs. However, significant knowledge gaps remain, including the following: (1) an atomic model of the structure of the pre-contraction outer sheath; (2) the composition and an atomic model of the baseplate and membrane complex; and (3) the composition of the Francisella central spike and secreted effector protein complex and an atomic model of its interaction with the sheath, baseplate, and membrane complex in the pre-contraction state and during the contraction process. To fill these gaps, we propose to carry out three major structure-function studies on T6SS using Francisella novicida [and its closely related F. tularensis live vaccine strain (LVS)] as a model. First, we shall obtain the atomic model of the sheath and tube complex in purified T6SS in its pre-contraction state with cryoEM, and elucidate the energetics and mechanism of T6SS contraction by structural comparison with the contracted sheath and structure-guided mutagenesis. Second, using proximity labeling, crosslinking, affinity pull-down, immunoblotting, proteomics, and bacterial 2-hybrid analyses, we shall determine the composition and protein interactions of the baseplate and membrane core complex. This information will be used in conjunction with cryo electron tomography of T6SS-containing mini-cells to determine the composition and structure of the T6SS baseplate and membrane complex in their pre- and post-contraction states. Third, we shall determine the composition and structure of the Francisella T6SS central spike and secreted effector complex. The results will form the foundation for future function studies and the development of new strategies for treating and preventing diseases caused by the numerous important pathogenic bacteria that have a T6SS.
项目总结/摘要 土拉热弗朗西丝菌是一种引起土拉菌病的细菌, 即使经过适当的治疗也是致命的。由于其感染剂量低,易于通过气溶胶传播, 毒力、F.土拉热被美国联邦政府列为一级选择代理。R 01项目 建立在我们早期对弗朗西斯菌VI型分泌系统的鉴定(通过联系PI Horwitz的小组)的基础上 (T6 SS)和我们随后确定(由Horwitz和MPI Zhou的小组)的第一个原子模型, 鞘及其独特的中央穗复合体通过低温电子显微镜(cryoEM)。T6 SS是 革兰氏阴性细菌用来感知环境信号的大型、复杂、多蛋白质纳米机器, 将毒素传递到其他细菌或真核宿主中;在弗朗西斯菌中,它们介导吞噬体逃逸, 胞质内复制它们是重要的毒力决定因子,存在于25%的革兰氏阴性杆菌中。 细菌,甚至更高比例的人类病原体。然而,在不知道 T6 SS的组成和结构,我们不能完全了解其发病机制,也不能有效地 设计对抗无数细菌疾病的对策。Francisella的T6 SS均显著高于 弗朗西斯菌属及其亲缘菌的高感染性和致死性, 与其他T6 SS相比,然而,仍然存在重大的知识差距,包括: (1)收缩前外鞘结构的原子模型;(2)成分和原子模型 基板和膜复合体的模型;(3)弗朗西斯菌中央棘突的组成, 分泌的效应蛋白复合物及其与鞘、基板和细胞膜相互作用的原子模型。 在收缩前状态和收缩过程中的膜复合物。 为了填补这些空白,我们建议对T6 SS进行三项主要的结构-功能研究, Francisella novicida及其近缘种F.土拉热活疫苗株(LVS)]作为模型。一要 获得了纯化的T6 SS中鞘管复合物在其预收缩状态下的原子模型, cryoEM,并阐明能量和机制的T6 SS收缩的结构比较, 收缩鞘和结构导向诱变。第二,利用邻近标记、交联、亲和 下拉,免疫印迹,蛋白质组学和细菌双杂交分析,我们将确定组成 以及基板和膜核心复合物的蛋白质相互作用。这些信息将用于 结合含有T6 SS的微型细胞的冷冻电子断层扫描以确定组成, T6 SS基板和膜复合物在收缩前和收缩后状态的结构。三是 应确定弗朗西斯菌T6 SS中央棘突和分泌效应子的组成和结构 复杂.研究结果将为未来的功能研究和新策略的制定奠定基础 用于治疗和预防由许多具有T6 SS的重要病原菌引起的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARCUS AARON HORWITZ其他文献

MARCUS AARON HORWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARCUS AARON HORWITZ', 18)}}的其他基金

Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
  • 批准号:
    10115911
  • 财政年份:
    2021
  • 资助金额:
    $ 54.97万
  • 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
  • 批准号:
    10372028
  • 财政年份:
    2021
  • 资助金额:
    $ 54.97万
  • 项目类别:
Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
基于精确控制的复制限制结核分枝杆菌,开发出比卡介苗更安全、更有效的新型结核疫苗,该疫苗经过精心设计,可实现最佳的体内生长和清除
  • 批准号:
    10570976
  • 财政年份:
    2021
  • 资助金额:
    $ 54.97万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10462669
  • 财政年份:
    2020
  • 资助金额:
    $ 54.97万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10120412
  • 财政年份:
    2020
  • 资助金额:
    $ 54.97万
  • 项目类别:
Composition, Atomic Structure and Function of the Francisella Type 6 Secretion System, a Distinct Subtype Essential for Phagosomal Escape, Intracellular Replication, and Virulence
弗朗西斯菌 6 型分泌系统的组成、原子结构和功能,这是吞噬体逃逸、细胞内复制和毒力所必需的独特亚型
  • 批准号:
    10685383
  • 财政年份:
    2020
  • 资助金额:
    $ 54.97万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    10837445
  • 财政年份:
    2019
  • 资助金额:
    $ 54.97万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    10308602
  • 财政年份:
    2019
  • 资助金额:
    $ 54.97万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    9815937
  • 财政年份:
    2019
  • 资助金额:
    $ 54.97万
  • 项目类别:
Development of a Safe and Potent Vaccine Against Melioidosis using the LVS dcapB Vector Platform
使用 LVS dcapB 载体平台开发安全有效的类鼻疽疫苗
  • 批准号:
    10159194
  • 财政年份:
    2019
  • 资助金额:
    $ 54.97万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 54.97万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了